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b-site APP-cleaving enzyme (BACE) is required
for production of the Alzheimer’s disease (AD)-
associated Abprotein. BACE levels are elevated
in AD brain, and increasing evidence reveals
BACE as a stress-related protease that is upre-
gulated following cerebral ischemia. However,
the molecular mechanism responsible is un-
known. We show that increases in BACE and
b-secretase activity are due to posttranslational
stabilization following caspase activation. We
also found that during cerebral ischemia, levels
of GGA3, an adaptor protein involved in BACE
trafficking, are reduced, while BACE levels are
increased. RNAi silencing of GGA3 also ele-
vated levels of BACE and Ab. Finally, in AD brain
samples, GGA3 protein levels were significantly
decreased and inversely correlated with in-
creased levels of BACE. In summary, we have
elucidated a GGA3-dependent mechanism reg-
ulating BACE levels and b-secretase activity.
This mechanism may explain increased cerebral
levels of BACE and Ab following cerebral ische-
mia and existing in AD.
INTRODUCTION
A key neuropathological event in Alzheimer’s disease (AD)
is the cerebral accumulation of an4 kDa peptide termed
amyloid b-protein (Ab), the principle component of senile
plaques. The Ab peptide is derived by serial proteolysis
of b-amyloid precursor protein (APP) by b-secretase at
the N terminus followed by g-secretase at the C terminus
(De Strooper and Annaert, 2000). b-secretase has been
identified as a novel membrane-tethered member of the
aspartyl proteases, termed BACE for b-site APP-cleaving
enzyme (Sinha et al., 1999; Vassar et al., 1999). BACE isan N-glycosylated type 1 transmembrane protein that
undergoes constitutive N-terminal processing in the Golgi
apparatus. The ectodomain contains four glycosylation
sites and two signature sequences typically associated
with aspartyl proteases (D T/S G T/S). BACE is targeted
through the secretory pathway to the plasma membrane
where it can be internalized to endosomes (Citron, 2004).
The BACE C-terminal fragment (CTF) contains a specific
di-leucine (DXXLL) sorting signal that is present in several
transmembrane proteins (e.g., cation-dependent [CD]
and cation-independent [CI] mannose 6-phosphate recep-
tor [MRP]) and regulates endocytosis, and, ultimately, ly-
sosomal degradation (Bonifacino and Traub, 2003). Muta-
genesis of LL to AA results in retention of BACE at the
plasma membrane (Huse et al., 2000; Pastorino et al.,
2002). Furthermore, the di-leucine motif may play a role
in BACE degradation since BACELL/AA mutations in-
crease protein levels of BACE (Pastorino et al., 2002).
More recently, we reported that BACE is normally de-
graded in lysosomes, and that mutagenesis of the di-
leucine motif in the BACE CTF prevents accumulation of
BACE in the lysosomes following inhibition of lysosomal
hydrolases (Koh et al., 2005). The BACE acidic di-leucine
motif has been shown to bind Golgi-localized g-ear-
containing ARF binding proteins (GGA)1, 2, and 3, and
phosphorylation of BACE-S498 appears to increase their
binding (He et al., 2002, 2003; Shiba et al., 2004; von Arnim
et al., 2004; Wahle et al., 2005).
GGA1, 2, and 3 are monomeric adaptors that are
recruited to the trans-Golgi network by the Arf1-GTPase.
They consist of four distinct segments: a VHS (VPS27,
Hrs, and STAM) domain that binds the acidic di-leucine
sorting signal DXXLL; a GAT (GGA and Tom1) domain,
which binds Arf:GTP; a hinge region which recruits cla-
thrin; and a GAE (gamma-adaptin ear homology) domain,
which exhibits sequence similarity to the ear region of
g-adaptin and recruits a number of accessory proteins.
GGAs are necessary for the sorting of acid hydrolases to
the lysosomes. Newly synthesized acid hydrolases modi-
fied with mannose 6-phosphate groups bind to MPRs.
MPRs bind to the VHS domain of GGAs via the DXXLLNeuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc. 721
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transport from the Golgi complex to the endosome of pro-
teins containing the DXXLL signal. However, Puertollano
and Bonifacino (2004) have recently reported that the
GGA3 GAT domain binds ubiquitin, and that ubiquinated
GGA3 is necessary for the delivery of activated epithelial
growth factor receptor (EGFR) to lysosomes. RNAi silenc-
ing of GGA3, but not GGA1 or 2, resulted in the accumu-
lation of EGFRs in enlarged early endosomes and partially
blocked their delivery to lysosomes, where they are
normally degraded. These findings indicate that GGAs
may be involved in the delivery of endosomal cargoes to
lysosomes. Recently, it has also been shown (He et al.,
2005) that RNAi silencing of GGA1, 2, and, 3 significantly
increases the levels of BACE in endosomes.
Increasing evidence suggest that BACE is a stress-
induced protease. BACE levels increase in cells that are
exposed to oxidative stress (Tamagno et al., 2002, 2003,
2005; Tong et al., 2005); in in vivo animal models following
traumatic brain injury (TBI) (Blasko et al., 2004), cerebral
ischemia (Wen et al., 2004), and impaired energy metabo-
lism (Velliquette et al., 2005); and in AD brains (Fukumoto
et al., 2002; Holsinger et al., 2002; Li et al., 2004a; Tyler
et al., 2002; Yang et al., 2003). The mechanisms underly-
ing such increases remain unknown. In the current study,
we report that BACE protein levels and consequently,
b-secretase cleavage of APP, are potentiated during
apoptosis. In exploring the mechanism underlying this
apoptotic event, we found that the elevation in BACE
following caspase activation is due to posttranslational
stabilization owing to a significant impairment in the deg-
radation and turnover of BACE. Given our previous find-
ings that BACE is normally degraded in the lysosomes,
and since the C-terminal di-leucine motif is required for
trafficking to lysosomes, we next investigated the fate of
GGA3 during apoptosis. We discovered that GGA3 is
a caspase-3 substrate that is cleaved during apoptosis.
This was shown both in vitro, in cell cultures, and in vivo,
in a rat model of cerebral ischemia. Moreover, we ob-
served that as GGA3 is removed by caspase cleavage,
BACE is stabilized, leading to elevated b-secretase cleav-
age of APP. In further support of our hypothesis that GGA3
plays a key role in BACE degradation, we show that RNAi
silencing of GGA3 increases levels of BACE, APP-C99,
and Ab. Finally, to begin to investigate whether decreased
GGA3 protein levels may account for increased BACE
levels and b-secretase activity in AD brains (Fukumoto
et al., 2002; Holsinger et al., 2002; Li et al., 2004a; Tyler
et al., 2002; Yang et al., 2003), we measured levels of
BACE and GGA3 in a series of AD and nondemented
(ND) control brain samples. While BACE protein levels
were significantly increased in the AD temporal cortex,
in contrast, GGA3 protein levels were significantly de-
creased and were inversely correlated with BACE levels
in the AD group, but not in the ND control group. These
data suggest that depletion of GGA3 is responsible for
enhanced BACE levels and b-secretase activity during
ischemia and existing in AD brain.722 Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc.RESULTS
Caspase Activation Increases BACE
and APP-C99 Levels
Apoptosis has been shown to enhance Ab levels in neuro-
nal and nonneuronal cells (Barnes et al., 1998; Galli et al.,
1998; Gervais et al., 1999; Guo et al., 2001; LeBlanc, 1995;
Sodhi et al., 2004; Tesco et al., 2003). Gervais et al. (1999)
proposed that caspase-mediated cleavage of APP at
APPD720 was responsible for increased Ab generation
associated with apoptosis. We subsequently showed
that increased levels of Ab following induction of apopto-
sis in CHO cells did not require caspase-mediated cleav-
age of APP at its C-terminal (D720) caspase site, its
N-terminal caspase sites, or both (Tesco et al., 2003)
(Figure 1A). In that same study we reported that 6 hr treat-
ment with STS significantly increased Ab1-total produc-
tion compared with untreated cells. The Ab enzyme-linked
immunosorbent assay (ELISA) measured Ab1-total using
biotinylated 3D6, which specifically recognizes the aspar-
tate in position 1 of Ab, as a reporter antibody. The ELISA
data demonstrated that the increase in Ab following cas-
pase activation is exclusively due to b-secretase cleavage
at position 1 and does not involve other Ab species start-
ing at other residues (e.g., at position 2 as expected from
a caspase cleavage in the b-secretase region). In the pres-
ent study, we investigated whether apoptosis-mediated
increases in Ab levels may be due to enhanced cleavage
of APP by BACE, the protease responsible for b-secretase
cleavage of APP (Vassar et al., 1999). For this purpose, we
tested whether apoptosis/caspase activation leads to
increased levels of APP-C99, the CTF generated by b-
secretase cleavage of APP. Western blot (WB) analysis
with the antibody WO2 (raised against amino acids 1–17
of Ab region) revealed that apoptosis induced by stauro-
sporine (STS) resulted in increased levels of C99 in H4
human neuroglioma cell lines expressing APP-751 (H4-
APP751) (Figure 1B). WB analysis with an antibody recog-
nizing the caspase-3 active fragment showed that
caspase-3 activation occurs as early as 6 hr following
treatment with STS. It should be noted that we also
observed a small increase in APP-C99 and activated cas-
pase fragment in untreated cells after 12 and 24 hr, most
likely due to marginal caspase activity triggered by serum
deprivation, which is known to activate caspases in cells
of neuronal origin. The loading control for caspase-3 and
WO2 blots is the same as that shown in Figure 1D.
A 6.5 kDa fragment corresponding to caspase cleavage
at D720 (APP-C99DC31) was also detected in apoptotic
H4-APP751 as previously described (Tesco et al., 2003).
These data agree with those of LeBlanc et al. (1999) who
reported that the generation of a 6.5 kDa fragment
precedes the increased production of both secreted and
intracellular Ab in apoptotic neurons. However, LeBlanc
et al. (1999) proposed that the 6.5 kDa fragment was gen-
erated by caspase-mediated cleavage at D653 (Figure 1A).
A caspase 6-like site (VKMD) has been identified at D653
in the b-secretase region of APP (Gervais et al., 1999;
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(A) Schematic representation of APP caspase sites and antibody recognition sites.
(B) Apoptosis was induced in human H4 neuroglioma cells expressing APP-751 by STS treatment. WB analysis performed with WO2 antibody
revealed APP-C99 and APP-C99DC31 during time course experiments. WB analysis with anti-caspase-3 active fragment antibody showed cas-
pase-3 activation as early as 6 hr following STS treatment. Limited caspase activity and a small increase of APP-C99 in the untreated cells at time
point 12 (horizontally compressed band) and 24 hr was also detected in the control sample since the control cells were grown in serum-free media.
(C) WB analysis with an antibody, ASP-1 (Oncogene), that recognizes only the first aspartyl residue of Ab region confirmed that the 12 kDa APP frag-
ment, whose levels increase following caspase activation, is APP-C99 in the H4-APP751 cells as well as the human SH-SY5Y and murine N2A cells
expressing only endogenous APP.
(D and E) WB analysis with anti-BACE antibody revealed increased BACE protein levels following apoptosis induced by STS or etoposide treatment,
respectively. Cu,Zn-SOD or b-tubulin was used as a loading control. Densitometry analysis was performed using NIH Image software. The graphs
represent BACE levels expressed as a percentage increase versus BACE level in control cells (100%). Each bar represents the mean ± SEM of at
least three experiments.LeBlanc et al., 1999), and it has been reported that the
APP Swedish mutation KM/NL improves the likelihood
that caspase 6 can cleave at this site (Gervais et al.,
1999). Caspase cleavage between D653 and A654 is ex-
pected to generate an APP-CTF that could be termed
C98 starting with A654. In contrast, b-secretase generatesAPP-C99 starting with D653. WB analysis with an anti-
body that recognizes only the first aspartyl residue of Ab
region, ASP-1 (Oncogene), confirmed that the 12 kDa
APP fragment, whose levels increase following caspase
activation, is APP-C99. This was shown to be the case in
the H4-APP751 cells, and also in human SH-SY5Y andNeuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc. 723
Neuron
BACE Levels and Activity Are Modulated by GGA3murine N2A cells expressing only endogenous APP
(Figure 1C).
We next asked whether the increased levels of APP-C99
were due to increased levels of endogenous BACE in the
H4-APP751 cells. We found that BACE protein levels were
increased 6-fold and 9-fold after 12 or 24 hr of STS
treatment, respectively (Figure 1D). Next, to confirm that
increased BACE protein levels were the result of caspase
activation, we used a different apoptotic inducer, etopo-
side. Apoptosis induced by etoposide also increased
BACE protein levels, albeit with a different time course
(Figure 1E). Inhibition of caspase activity by zVAD pre-
vented BACE accumulation in both treatments (Figures
1D–1E). As a control for protein loading, the same blots
were reprobed with anti-Cu,Zn-SOD and anti-b-tubulin an-
tibodies, respectively. We chose to use unrelated proteins
(for which sensitive antibodies were available and most
effective) as loading controls for each set of experiments.
The use of two different loading controls serves to confirm
our findings. Using the anti-BACE antibody currently avail-
able, detection of steady-state levels of BACE is not as
robust as detection of steady-state levels of APP-C99.
Thus, the apparent discrepancy between the increase in
C99 levels at 6 hr and the absence of increase of BACE
levels is most likely due to the difference in the sensitivity
of the antibodies used for detection of BACE versus
APP-C99. However, we cannot rule out the possibility that
generation of the C99 fragment earlier (6 hr) in the STS
model is BACE-independent, but caspase-dependent.
These findings were also confirmed in CHO cells express-
ing BACE and APP-751 and in primary neuronal cultures
obtained from E15 embryos of transgenic mice expressing
human APP with the Swedish mutation (KM670/671NL)
(SWE) (data not shown). These results indicate that cas-
pase activation increases protein levels of BACE and
potentiates b-secretase-mediated processing of APP in
neuronal and nonneuronal cell cultures.
Caspase Activation Increases the Half-Life of BACE
We next asked whether apoptosis increases protein levels
of BACE via increased gene expression. BACE mRNA
levels were not increased but were virtually undetectable
after only 6 hr of STS treatment in the H4-APP751 cells
(Figure 2A). The preservation of 28S and 18S ribosomal
RNA ruled out nonspecific RNA degradation (Figure 2A).
This led us to ask whether BACE protein levels were in-
creased during apoptosis due to decreased degradation.
Pulse-chase analyses revealed that the approximate
half-life of BACE was9 hr under normal conditions. How-
ever, following caspase activation, BACE levels did not
significantly decrease (Figures 2B and 2C). In contrast,
the half-lives of tumor necrosis factor-a (TNF) converting
enzyme (TACE) (Figures 2D and 2E) and full-length APP
(and APP-CTFs) (Figure 2F) were not increased during ap-
optosis. In confirmation of these findings, the approximate
half-life of endogenous BACE was roughly 10 hr under
normal conditions in cycloheximide (CHX) time course ex-
periments. However, following caspase activation, BACE724 Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc.levels did not significantly decrease, even after 30 hr into
the time course. Given that BACE is stabilized during apo-
ptosis while many other proteins are degraded at normal or
accelerated rates (e.g., APP and TACE), the apparent in-
crease of BACE protein levels at the latest time points of
the CHX+STS time course was most likely due to a relative
increase of stabilized BACE when normalized for equal
amounts of total protein. The half-lives of the negative con-
trol, TACE, and APP were somewhat decreased during
apoptosis (Figure 2G). A possible explanation for the ap-
parent discrepancy between BACE half-life (9–10 hr) and
a 6-fold increase in BACE protein levels after 12 hr treat-
ment with STS is that BACE levels in these studies are
relative to total protein during the apoptotic time course.
As measured, BACE levels are determined relative to
amounts of total protein loaded equally throughout the
time course. Thus, absolute BACE levels are not increasing
during apoptosis; BACE levels are only increasing as a per-
centage of total cellular protein. Since BACE is being sta-
bilized during apoptosis, while many other proteins are
succumbing to caspase cleavage, e.g. SOD and GGA3,
BACE levels remain fairly constant in the cell during apo-
ptosis due to a significantly longer half-life. This translates
into the detection of increased levels of BACE per total
amount of cell protein during the apoptosis time course.
The BACE Trafficking Molecule GGA3 Is Cleaved
by Caspase-3 during Apoptosis
We have previously reported that endogenous BACE is
normally degraded by lysosomal hydrolases (Koh et al.,
2005). Thus, we hypothesized that caspase activation
leads to BACE stabilization by interfering with its degrada-
tion in the lysosomes. We previously reported that the
BACE di-leucine motif, the binding site for GGAs, plays
a role in targeting BACE to the lysosomes (Koh et al.,
2005). Since GGA3 has been shown to be necessary for
lysosomal degradation of EGFR (Puertollano and Bonifa-
cino, 2004), we hypothesized that GGA3 may play a role
in the sorting of BACE to the lysosomes and that caspase
cleavage of GGA3 during apoptosis may impair the degra-
dation of BACE.
We first asked whether GGA3 is cleaved by caspases
during apoptosis. For this purpose, H4-APP751 cells were
treated with STS during time course experiments. WB
analysis with an anti-GGA3 antibody targeted to a portion
(amino acids 424–542) of the hinge domain of GGA3 (Fig-
ure 3F) revealed that full-length GGA3 is cleaved into two
major fragments of 48 and 37 kDa during apoptosis.
b-catenin, which is a known caspase-3 substrate (Branco-
lini et al., 1998), was cleaved in the H4-APP751 cells with
a temporal pattern similar to that observed for GGA3 (Fig-
ure 3A). It is important to note that the fragments were not
detected at the 24 hr time point. The latter is most likely
due to their degradation during the progression of apopto-
sis. Since many proteases are activated during apoptosis,
we next employed an in vitro cell-free assay to determine
whether caspase-3 is capable of cleaving GGA3 to
produce 48 and 37 kDa fragments. Recombinant
Neuron
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(A) Northern blot analysis: H4-APP751 cells were treated with STS during time course experiments. Total RNA was extracted, and 20 mg of the
resulting RNA was analyzed by northern blotting with BACE cDNA. Ethidium staining of the gel (lower panel) confirmed equal RNA loading and
absence of nonspecific degradation.
(B) Pulse-chase analysis. H4-APP751 cells were transiently transfected with BACE-Myc cDNA and were metabolically labeled after 24 hr. Lysates
from each time point were immunoprecipitated with anti-Myc antibody.
(C) Protein amounts were quantified by phosphorimager and represented in the graph. The mean ± SEM of at least three experiments is shown.
(D–F) For the TACE and APP pulse-chase analysis, H4-APP751 cells were metabolically labeled. Lysates from each time point were immunoprecip-
itated with anti-TACE or anti-APP (A8717) antibody. Protein amounts were quantified by phosphorimager and represented in the graph. The mean ±
SEM of at least three experiments is shown.
(G) Cycloheximide (CHX) degradation time course: BACE, TACE, and APP proteins were detected by WB at various times after addition of CHX
(40 mg/ml) only or STS + CHX in H4-APP751 cells. The degradation of BACE was decreased while the degradation of TACE and APP was unchanged
during apoptosis.caspase-3 cleaved in vitro translated [35S]-labeled GGA3
into several fragments (Figure 3B). To determine which of
these fragments corresponded to the ones detected by
WB analysis of the apoptotic lysates, GGA3 was in vitro
translated in the presence of cold methionine and then
incubated with recombinant caspase-3. WB analysis withanti-GGA3 antibody revealed that recombinant caspase-3
cleaves in vitro translated GGA3 into three major frag-
ments consisting of the 48 and 37 kDa bands, along
with a third band at 50 kDa (Figure 3C). Meanwhile, the
additional caspase-3-derived fragments detected in the
autoradiograph are most likely N-terminal fragmentsNeuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc. 725
Neuron
BACE Levels and Activity Are Modulated by GGA3Figure 3. The BACE Trafficking Molecule GGA3 Is Cleaved by Caspase-3 during Apoptosis
(A) Apoptosis was induced in H4-APP751 cells by STS treatment during time course experiments. WB analysis with an anti-GGA3 antibody revealed
cleavage of GGA3 in two major fragments of 48 and 37 kDa (indicated by the arrows) in apoptotic H4 cells, which was prevented by caspase
inhibition (zVAD). A longer exposure (Longer exp) better evidentiates the caspase-derived fragments. WB analysis with anti-b-catenin antibody re-
vealed that b-catenin was cleaved by caspase (casp-fragment) in the H4-APP751 cells with a temporal pattern similar to that observed for GGA3.
(B) Recombinant caspase-3 cleaves in vitro translated GGA3 (labeled with [35S] methionine) in several fragments. The stars indicate the fragments
detected by WB in Figure 3A. The additional fragments are most likely caspase-derived N-terminal fragments (NTFcas).
(C) Recombinant caspase-3 cleaves in vitro translated GGA3 (cold methionine) in three fragments detected in WB by anti-GGA3 antibody (stars
indicate the fragments).
(D) Recombinant caspase-3 cleaves endogenous GGA3 from lysates of control cells with a pattern similar to the one observed in H4 apoptotic lysates
(stars indicate the fragments).
(E) Apoptosis induced in H4 cells stably overexpressing GGA3 produces a cleavage of GGA3 identical to the one produced by recombinant caspase-3
(stars indicate the fragments). Nonspecific bands are also detected just below the48 kDa fragment and in correspondence of the37 kDa fragment
(not specific).
(F) Schematic representation of GGA3 caspase cleavage.based on the epitope of the anti-GGA3 antibody
(Figure 3F).
We then assessed whether recombinant caspase-3
cleaves endogenous GGA3 from normal cell lysates and
in vitro translated GGA3 to produce similar sets of frag-
ments. Lysates of control cells were incubated with re-
combinant caspase-3 at 37C for 2 hr. WB analysis with
the anti-GGA3 antibody revealed that recombinant cas-
pase-3 cleaves endogenous GGA3 to generate a pattern
of fragments similar to that observed in the in vitro assay726 Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc.(three fragments). Treatment of cell lysates with recombi-
nant caspase-3 generated an 50 kDa GGA3 fragment
(Figure 3D) that was not observed in the H4 apoptotic
lysates (Figure 3A). One possible explanation is that its
levels were below the levels of detection in the apoptotic
cells. To address this possibility, H4 cells stably overex-
pressing GGA3 were treated with STS to induce caspase
activation. This led to cleavage of GGA3 into a pattern of
fragments (Figure 3E) that was identical to that produced
by recombinant caspase-3 cleavage of both in vitro
Neuron
BACE Levels and Activity Are Modulated by GGA3Figure 4. Site-Directed Mutagenesis of GGA3 at D313/D328/D333/D428 Prevents the Generation of the Three Major Caspase-
Derived Fragments
(A) Multiple sequence alignment of human (NP_619525), Mus musculus (NP_766636), Bos taurus (XP_587687) and Canis familiaris (XP_540429)
GGA3. Putative caspase consensus sequence in the hinge and GAE domains are in boxes. The red bar indicates the epitope recognized by the
anti GGA3 antibody. The hinge domain starts at D313 and ends at V599. The yellow and pink background indicates the GAT and GAE domains,
respectively.
(B) Site-directed mutagenesis of D313 to alanine prevents the caspase-3-mediated cleavage of in vitro translated GGA3 (labeled with cold methio-
nine) at one of the three major sites (WB with anti-GGA3 antibody).
(C) H4 cells were transiently transfected with empty vector, GGA3 wild-type (WT), and GGA3D313A/D328A/D333A/D428A. The overexpression of
GGA3 WT induced an artifactual caspase-mediated cleavage (stars indicate the fragments). The cleavage was inhibited when cells were treated
with zVAD during the transfection. The caspase-derived fragments were not detected in the GGA3-D313A/D328A/D333A/D428A when cells were
treated with STS. However, zVAD treatment, but not GGA3D313A/D328A/D333A/D428A, preserved full-length GGA3.translated GGA3 (Figure 3C) and endogenous GGA3 in
cell lysates (Figure 3D). Collectively, these data indicate
that caspase-3 cleaves GGA3 at three major sites. Given
the anti-GGA3 antibody epitope and the size of the frag-
ments generated during apoptosis, we predicted that
caspase-mediated cleavage of GGA3 occurs within the
hinge domain (Figure 3F) to produce three fragments
of 50 kDa (fragment 1), 48 kDa (fragment 2), and
37 kDa (fragment 3).
Site-Directed Mutagenesis of GGA3 at D313/D328/
D333/D428 Prevents the Generation of the Three
Major Caspase-Derived Fragments
Several putative caspase consensus sites, conserved in
the GGA3 sequence of mammals, can be identified in the
hinge domain (Figure 4A). Since the motif 310TLPD313 inGGA3 has previously been shown to serve as a caspase
site in the Golgi resident protein GRASP65 (Lane et al.,
2002), we performed site-directed mutagenesis of D313
to alanine. Next, wild-type GGA3 (WT) and mutated
GGA3 (D313A) were in vitro translated in the presence of
cold methionine and subjected to the in vitro caspase-3
cleavage assay as described above. WB analysis with
anti-GGA3 antibody revealed that the D313A mutation
prevented the generation of the caspase-derived 50
kDa fragment 1 (Figure 4B).
Subsequently, we mutagenized aspartates downstream
of D313 and found that D328A/D333A prevented the gen-
eration of fragment 2, while D428A prevented the genera-
tion of fragment 3 in the in vitro caspase-3 cleavage assay
as described above (data not shown). We next tested
whether all four mutations (D313A/D328A/D333A/D428A)Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc. 727
Neuron
BACE Levels and Activity Are Modulated by GGA3Figure 5. Caspase-Mediated Cleavage of GGA3 at D313
Generates a Dominant-Negative Molecule
(A) HA-tagged GGA3DN, HA-tagged GGA3 WT, or vector alone with
Myc-tagged BACE in H4-APP751 cells. WB analysis performed with
anti-HA antibody (Cell Signaling) revealed the expression of the GGA3
construct. WB analysis performed with anti-Myc (Cell Signaling) re-
vealed that BACE levels were increased in the cells expressing
GGA3DN when compared with those of cells expressing vector alone
or GGA3.
(B) The graph represents mean ± SEM of at least six BACE level mea-
surements. Densitometry was performed using Versadoc Imager and
QuantityOne software (Bio-Rad). BACE densitometry values were nor-
malized against GAPDH values. Unpaired t test with Welch correction728 Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc.could prevent caspase cleavage of GGA3 during apopto-
sis. H4 cells were transiently transfected with GGA3 WT
and GGA3-D313A/D328A/D333A/D428A, and then apo-
ptosis was induced by STS treatment. Overexpression of
GGA3 WT in H4 cells artifactually induced GGA3 caspase
cleavage, which was prevented by treatment with zVAD
(Figure 4C). As expected, the GGA3-D313A/D328A/D333A/
D428A did not produce fragments 1–3 following caspase
activation (Figure 4C). However, levels of full-length GGA3-
D313A/D328A/D333A/D428A were decreased under
these conditions, suggesting that GGA3 hosts additional
cleavage sites that render it susceptible to its degradation
during apoptosis.
Caspase-Mediated Cleavage of GGA3 at D313
Generates a Dominant-Negative Molecule
It has been previously shown that the moderate expres-
sion of a truncated GGA construct lacking the hinge and
GAE domain (GGA1 VHS+GAT) operates as a dominant-
negative (DN) that blocks the clathrin-dependent trans-
port of the CI-MPR from the TGN to the endosomes (Puer-
tollano et al., 2001). Thus, cleavage of GGA3 D313 at the
border of the hinge domain would not only reduce active
GGA3 molecules during apoptosis, but also potentially
generate the equivalent of a DN form of GGA3.
To address this possibility we engineered an HA-tagged
GGA3 N-terminal fragment 1-313 mimicking the N-termi-
nal caspase-derived fragment generated by cleavage at
D313 (GGA3DN). Then we cotransfected GGA3DN, HA-
tagged GGA3 WT, or vector alone with Myc-tagged BACE
in H4-APP751 cells (Figure 5A) and found that BACE levels
were increased in the cells expressing GGA3DN compared
with those in cells expressing vector alone or GGA3 (Fig-
ures 5A and 5B). Levels of secreted Ab40 also increased
in cells expressing GGA3DN (Figure 5C). However, the
increase was not statistically significant because the
GGA3DN most likely did not completely inhibit the endog-
enous GGA3. During apoptosis, however, caspase-medi-
ated cleavage of GGA3 results not only in the production of
GGA3DN, but also the degradation of GGA3.
RNAi Silencing of GGA3 Increases Levels
of BACE, APP-C99, and Ab
To determine whether GGA3 depletion plays a role in
BACE degradation, we assessed the effects of RNAi si-
lencing of GGA3 on BACE and Ab levels (as a measure
of b-secretase activity). H4 cells stably expressing WT
APP-751 or APP containing the Swedish FAD mutation
(APPSWE) were transfected with 200 nM siGGA3 to de-
plete GGA3. A 19 bp scrambled sequence was used as
negative control for siRNA (siNeg). Seventy-two hours
later, we measured GGA3 levels and found that
was used for statistical analysis. p = 0.0014 vector versus GGA3DN.
p = 0.0008 GGA3 WT versus GGA3DN.
(C) The graph represents mean ± SEM of at least six Ab0 measurements
by ELISA. Ab concentration was normalized against the concentration
of protein in cell lysates.
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BACE Levels and Activity Are Modulated by GGA3Figure 6. RNAi Silencing of GGA3 Increases Levels of BACE, APP-C99, and Ab
(A) H4-APP751 cells were transfected with 200 nM siRNA GGA3 or 200 nM siNeg control. After 72 hr, GGA3 protein levels were determined by WB
with anti-GGA3 antibody (Transduction Laboratories). GAPDH was used as loading control.
(B) After 72 hr, a sister plate of the same cells as in (A) was cotransfected with Myc-tagged BACE and siGGA3 or siNeg control. EGFR levels detected
by WB with anti-EGFR antibody (Cell Signaling) were increased in the siGGA3-treated cells. BACE protein levels were detected by WB using anti-Myc
polyclonal antibody (Cell signaling) were also increased in the siGGA3-treated cells. Levels of GAPDH were unchanged.
(C and D) the graph represents mean ± SEM of six or seven BACE level measurements for H4-APP751 and H4-APPSWE, respectively. Densitometry
was performed using Versadoc Imager and QuantityOne software (Bio-Rad). BACE densitometry values were normalized against GAPDH values.
Unpaired t test with Welch correction was used for statistical analysis.
(E) Full-length APP and APP-C99 levels were detected by WB with WO2 antibody in H4-APPSWE cells.
(F and G) The graph represents mean ± SEM of six or nine Ab0 measurements by ELISA in H4-APP751 or H4-APPSWE, respectively. Ab concentration
was normalized against the concentration of protein in cell lysates. Unpaired t test with Welch correction was used for statistical analysis.endogenous GGA3 was decreased by 50% (Figure 6A;
see Figure S1 in the Supplemental Data). At this same
time point, a sister plate of the same cells was cotrans-
fected with Myc-tagged BACE and either siGGA3 or
siNeg. The media was changed after 48 hr. Cells and media
were collected 72 hr after cotransfection, and BACE levels
were determined by WB using anti-Myc antibody. BACE
levels were increased by 7- and 4-fold in H4-APP751
and H4-APPSWE, respectively (Figures 6B–6D). Since
degradation of EGFR has previously been shown to be im-
paired in cells depleted of GGA3, as a positive control we
determined the effect of siRNA silencing of GGA3 on
EGFR in these same cells. As expected, decreased levels
of GGA3 resulted in increased levels of EGFR protein
(Figure 6B; Figure S1B). Meanwhile, as a negative control,
downregulation of GGA3 had no effect on levels of
GAPDH, which was also used as a loading control (Fig-
ure 6B). Similar results were observed in H4-APPSWE
cells (data not shown). In accord with these data, levels
of APP-C99, detected by WO2 antibody, were increased
while levels of full-length APP were unchanged in H4-
APPSWE cells depleted of GGA3 (Figure 5E). These data
indicate enhanced b-secretase activity. Next, we mea-
sured Ab40 levels in the media (conditioned for 24 hr) byELISA. Downregulation of GGA3 increased Ab40 levels
by >2-fold in H4-APP751 (Figure 5F) and by 50% in H4-
APPSWE cells (Figure 6G). As previously reported (Vassar
et al., 1999), increased levels of BACE enhance Ab pro-
duction to a lesser extent in cells expressing APPSWE
than in cells expressing APP WT. However, increased
levels of Ab corresponded well with the increase in
BACE levels in these experiments (Figure 6B). Similar
results were observed when H4 cells stably express-
ing Myc-tagged BACE were cotransfected with siGGA3
and either WT APP or APPSWE (data not shown). Our
aim was to assess b-secretase activity, and since
increases in BACE activity have previously been shown
to increase both Ab40 and Ab42 (Sinha et al., 1999;
Vassar et al., 1999; Yan et al., 1999), we did not measure
Ab42 in these experiments. We have confirmed that
downregulation of GGA3 increases BACE levels in murine
N2A cells using lentiviral vectors expressing shRNA for
mouse GGA3. Three shRNA lentiviral vectors downregu-
lated GGA3 to different degrees (Figures S2A and S2B).
Levels of ectopically expressed BACE inversely correlated
with GGA3 levels (Figures S2A–S2C). Moreover, endoge-
nous BACE also increased upon downregulation of
GGA3 (Figures S2D and S2E). To determine whetherNeuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc. 729
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RNAi has been performed in H4 cells expressing either
APP-751 or the APP-CTF (APP-C105) using lentiviral vec-
tors expressing shRNA for human GGA3 (Figure S3A). We
have found that downregulation of GGA3 produces an in-
crease in Ab40 generation in full-length APP-751-express-
ing cell lines, but not in the APP-C105-expressing cell lines
(Figures S3B and S3C, respectively). These results indi-
cate that depletion of GGA3 affects APP processing inde-
pendently of g-secretase activity. It is important to note
that BACE levels increase when depletion of GGA3 is
achieved with both synthetic RNAi duplex and lentiviral
vector expressing shRNA targeting different regions of the
GGA3 gene. Collectively, these findings show that down-
regulation of GGA3 serves to increase levels of BACE,
APP-C99, and Ab. These data also support the hypothesis
that GGA3 normally plays a role in modulating BACE
turnover and stability, most likely by sorting BACE to lyso-
somes (based on our earlier findings; Koh et al., 2005).
GGA3 Is Degraded during Cerebral Ischemia
Concurrently with Caspase Activation
and Increases in BACE Levels
BACE protein levels and activity have previously been
shown to be elevated following cerebral ischemia in a rat
model (Wen et al., 2004). Previous studies have also shown
that caspase-3 activation can be detected following cere-
bral ischemia from 1 to 24 hr after reperfusion in both mice
and rats (Davoli et al., 2002; Namura et al., 1998). We thus
asked whether caspase activation induced by cerebral is-
chemia leads to degradation of GGA3 and increased levels
of BACE protein in the same rat model of cerebral ischemia
used by Wen et al. (2004). Ischemic stroke was induced by
middle cerebral artery occlusion (MCAO) in rats as previ-
ously described (Liu et al., 2002). At 48 hr of reperfusion fol-
lowing induction of cerebral ischemia, BACE protein levels
were significantly increased (>2-fold) in the ischemic (ipsi-
lateral) cortical and subcortical hemispheres, but not in the
contralateral hemispheres (Figures 7A and 7B). Increased
levels of BACE were detected as early as 12 hr postreper-
fusion (data not shown). Unfortunately, we were unable to
detect caspases in the rat homogenates by WB. One pos-
sible explanation is that the anti-caspase antibodies are
human specific and thus unable to detect rat caspases. It
is also likely that caspase-3 activation occurs much earlier
than the 48 hr time point. Since APP is also a substrate for
caspase cleavage (Barnes et al., 1998; Gervais et al., 1999;
LeBlanc et al., 1999; Pellegrini et al., 1999; Weidemann
et al., 1999), we tested whether APP undergoes caspase-
mediated cleavage in the rat brain following ischemia.
At 48 hr of reperfusion following induction of cerebral
ischemia, full-length APP protein levels were slightly de-
creased owing to the processing of full-length APP into
a fragment of roughly 90 kDa (Figure 7A), which we have
previously reported to be the N-terminal APP caspase
fragment in cells undergoing apoptosis (Tesco et al.,
2003). Based on APP, caspase activation occurred con-
comitant with the increase in BACE levels.730 Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc.We next determined whether GGA3 undergoes cas-
pase-mediated cleavage during cerebral ischemia. At 12
and 48 hr of reperfusion following induction of cerebral is-
chemia, GGA3 was cleaved with a temporal pattern similar
to that observed for the increase in BACE protein levels
(Figure 7C). GGA3 full-length was decreased in the rat is-
chemic hemisphere samples and two cleavage fragments
were detected in the ischemic rat hemisphere: a fragment
of 50 kDa, most likely corresponding to fragment 1 gen-
erated by cleavage at D313 (Figure 3C), and a second
fragment of 28 kDa. The origin of the second fragment
is not clear; however, one possible explanation is that
the 28 kDa fragment may be the result of degradation of
the larger fragments detected in the in vitro experiments
(Figure 2 and Figure 3). In any event, these data indicate
that full-length GGA3 is cleaved and depleted following
ischemia. Moreover, depletion of GGA3 occurs concur-
rently with caspase activation (based on caspase cleav-
age of APP) and increasing levels of BACE in the rat model
of cerebral ischemia.
Levels of GGA3 Are Decreased and Inversely
Correlated with Increased Levels of BACE
in AD Temporal Cortex
Several studies have shown that BACE protein levels and
b-secretase activity are increased in AD brains (Fukumoto
et al., 2002; Holsinger et al., 2002; Li et al., 2004a; Tyler
et al., 2002; Yang et al., 2003). However, the molecular
mechanism underlying these increases remains unre-
solved. The data presented in this study raise the possibil-
ity that increased BACE levels in AD brains may be at least
partly due to decreased levels of GGA3. To test this hy-
pothesis, we measured GGA3 and BACE protein levels in
19 ND and 20 AD brain (temporal cortex) samples that
have already been shown to possess increased BACE
levels and b-secretase activity (Li et al., 2004a; Tyler et al.,
2002). We first confirmed that BACE protein levels are sig-
nificantly increased in the AD temporal cortex (Figures 8A
and 8B) as shown by WB analysis using the SECB1 anti-
body (Li et al., 2004a; Tyler et al., 2002). Next, we found
that GGA3 protein levels were significantly decreased
in the same set of AD brains (Figures 8A–8C). Moreover,
the decreased levels of GGA3 were inversely correlated
with the increased BACE levels in the AD group, but not
in the ND group (Figures 8D and 8E). Quantification of
GGA3 mRNA levels by real-time PCR showed that the de-
crease in GGA3 protein levels is not due to reduced gene
expression (Figure 8F) but most likely occurs at the trans-
lational or posttranslational level. We next asked whether
reduced levels of GGA3 in the AD brains could be due to
degradation by caspase-3. Levels of full-length caspase-
3 were decreased in the AD (but not ND) brains, most likely
because of increased activation as shown to occur in apo-
ptotic H4 cells (i.e. those treated with STS) (Figure 8G).
However, we were unable to detect either the active cas-
pase-3 fragment or the caspase-derived GGA3 fragments
in these brains. One possible explanation is that the cas-
pase-generated fragments were readily degraded in these
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BACE Levels and Activity Are Modulated by GGA3Figure 7. GGA3 Is Degraded during Cerebral Ischemia Concurrently with Caspase Activation and Increased BACE Levels
(A) Cerebral ischemia was induced by middle cerebral artery occlusion for 1 hr in female rats. After desired times of reperfusion, the animals were
sacrificed. The brains were dissected in the ischemic (ipsilateral, I) and nonischemic (contralateral, C) hemispheres and each hemisphere in cortex
(Ctx) and subcortex (Sub-Ctx). (A and B) WB analysis with anti-BACE antibody (Affinity Bioreagents) revealed an increase in BACE protein levels in the
ischemic hemisphere (samples were run in duplicate) after 48 hr of reperfusion. b-tubulin was used as loading control. The densitometry analysis of
BACE after normalization against b-tubulin levels is represented in the graph. Mean ± SEM of five rats is shown. Statistical analysis was performed
using Mann-Whitney test. WB with an anti-APP-CTF antibody (A8717, Sigma) revealed an APP caspase-derived fragment in the rat ischemic hemi-
sphere (samples were run in duplicate) after 48 hr of reperfusion. (C) WB analysis with anti-GGA3 antibody showed that GGA3 full-length was
decreased during ischemia after 12 and 48 hr of reperfusion (C, contralateral hemisphere; I, ipsilateral hemisphere; SubCtx, subcortex; Ctx, cortex).
A longer exposure of the same blot revealed the presence of two fragments of GGA3 in the ispilateral hemisphere.postmortem tissues. On the other hand, the GGA3 cas-
pase-derived fragments were also not detectable in cells
during advanced apoptosis (Figure 3A). To further investi-
gate the mechanism underlying the observed depletion of
GGA3 in the AD brains, we have analyzed BACE and GGA3
levels not only in the temporal cortex, but also in the
cerebellum, which is usually spared of AD pathology
(Figure S4). GGA3 levels were decreased in the cerebellum
of AD subjects as compared with control subjects by 40%
(Figure S4C). However, the decrease was more pro-
nounced in the temporal cortex (55%) (Figure 8). Moreover,
while decreased levels of GGA3 inversely correlated with
BACE levels in the temporal cortex, BACE levels were
not increased in the cerebellum of AD as compared with
those of control subjects (Figures S4A–S4B), suggesting
that the levels of GGA3 were sufficient for a normal degra-dation of BACE. The generation of GGA3 null mice, which
are currently not available, will be useful for determining the
threshold level of GGA3 depletion required to impair BACE
degradation in vivo. While GGA3 levels in the temporal cor-
tex correlate with GGA3 levels in the cerebellum in ND
(Figure S4D), such correlation is lost in the AD patients in
which the levels of GGA3 are further reduced in the tempo-
ral cortex (Figure S4E). These data suggest that subjects
with lower levels of GGA3 (Figure S4F) could be at risk of
developing AD in conditions associated with caspase acti-
vation, e.g cerebral ischemia or Ab toxicity, affecting se-
lected brain regions. These findings lend further support
to the hypothesis that GGA3 normally plays a role in mod-
ulating BACE turnover and stability, and that pathological
conditions in which GGA3 levels are reduced lead to
increased levels of BACE and b-secretase activity.Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc. 731
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BACE Levels and Activity Are Modulated by GGA3Figure 8. Levels of GGA3 Are Decreased and Are Inversely Correlated with Increased Levels of BACE in AD Brains
(A) WB analysis of temporal cortex of human brains. AD, Alzheimer’s disease. ND, nondemented control. BACE was detected by SECB1. GGA3 was
detected by anti-GGA3 antibody. GAPDH was used as loading control.
(B and C) BACE and GGA3 densitometry values were normalized against GAPDH values. At least a triplicate of each sample was analyzed. The graphs
represent mean ± SEM of 19 ND and 20 AD subjects. Unpaired t test and unpaired t test with Welch correction were used to perform statistical
analysis of BACE and GGA3 levels, respectively.
(D and E) Linear correlation analysis between BACE and GGA3 levels in AD and ND subjetcs, respectively. The dotted line indicates the 95% con-
fidence interval.
(F) GGA3 mRNA was quantified by real-time PCR. The graph represents mean ± SEM of 10 ND and 10 AD subjects. SQ, starting quantity. Please note
that the levels of GGA3 protein were significantly decreased in the same samples.
(G) WB analysis of temporal cortex of human brains. AD, Alzheimer’s disease. ND, nondemented control. Full-length caspase-3 was detected with
anti-caspase-3 antibody. To show that full-length caspase-3 decreased during apoptosis, lysates from control (C), lysates treated with (STS), and
lysates treated with STS+zVAD H4 cells were also included. GAPDH was used as loading control.732 Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc.
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Recent studies have revealed BACE as a stress-related
protease that is upregulated in the brains of AD patients
(Fukumoto et al., 2002; Holsinger et al., 2002; Li et al.,
2004a; Tyler et al., 2002; Yang et al., 2003). BACE levels
have also been shown to increase following ischemia
(Wen et al., 2004); however, the molecular mechanism
responsible has remained elusive. Here, we show that
caspase activation elevates BACE levels and b-secretase
activity owing to posttranslational stabilization of BACE.
Using a rat ischemia model, we found that levels of GGA3,
an adaptor molecule implicated in BACE trafficking, are
reduced in a temporally coordinated manner with caspase
activation and increases in BACE proteins levels. In cell-
based studies, RNAi silencing of GGA3 directly led to
increased BACE protein levels and b-secretase activity
as evidenced by enhanced APP-C99 and Ab levels. To-
gether, these data suggest a model in which apoptosis
(e.g., that induced by ischemia) drives the depletion of
GGA3, which, in turn, leads to the stabilization of BACE
and increased b-secretase activity. We also analyzed brain
samples of AD patients in which BACE levels and b-secre-
tase activity have previously been shown to be elevated
in the temporal cortex. In further support of our model of
GGA3-dependent degradation/stabilization of BACE, in the
brains of AD patients, GGA3 protein levels were significantly
decreased. Moreover, this decrease was inversely corre-
lated with increased BACE levels in the temporal cortex.
Decreased levels of GGA3 most likely engender an in-
crease in BACE protein levels by interfering with the sort-
ing of BACE to lysosomes where it is degraded (Koh et al.,
2005). GGA3 has previously been demonstrated to target
cargo (e.g., EGFR) to lysosomes (Puertollano and Bonifa-
cino, 2004). RNAi silencing of GGA3 resulted in the accu-
mulation of EGFRs in enlarged early endosomes and par-
tially blocked their delivery to lysosomes where they are
normally degraded. These studies indicate that GGA3 is
involved in the delivery of endosomal cargoes to lyso-
somes. Recently, He et al. (2005) showed that RNAi silenc-
ing of GGAs significantly increases the levels of BACE in
endosomes. They also proposed that GGAs are neces-
sary for BACE and MPRs to be transported back to
TGN. However, BACE turnover was not assessed in that
study, and the accumulation of BACE in endosomes could
also be due to decreased degradation resembling the
effect of GGA3 downregulation on EGFR degradation (Pu-
ertollano and Bonifacino, 2004). The mechanism by which
GGA3 targets some cargo (e.g., EGFR) to lysosomes has
been shown to be ubiquitin dependent (Puertollano and
Bonifacino, 2004). While there is some evidence that BACE
is ubiquitinated (Qing et al., 2004), future studies will be
required to determine whether GGA3-dependent degra-
dation of BACE requires ubiquitination or whether it oc-
curs via an alternate mechanism (e.g., via binding to the
GGA3-VHS domain).
We have shown that caspase-mediated degradation of
GGA3 occurs following cerebral ischemia, and we pro-pose that it may explain our and others’ observations of el-
evated b-secretase levels (and activity) following cerebral
ischemia. As shown in the Nun Study (Kalaria, 2000; Nolan
et al., 1998; Snowdon et al., 1997), and as recently con-
firmed in additional prospective autopsy studies (Petro-
vitch et al., 2005; Riekse et al., 2004), individuals with AD
and cerebrovascular pathologies show greater cognitive
impairment than those exhibiting either pathology alone.
These studies indicate that there is an additive or syner-
gistic interaction between AD and cerebrovascular pathol-
ogies. Furthermore, evidence is accumulating that stroke
and transient ischemic attacks significantly increase the
risk of AD in elderly individuals (Honig et al., 2003; Zlo-
kovic, 2002). A recent family-based study has shown that
stroke increases the risk of AD to a similar extent as the
presence of an APOE-34 allele in Latinos (Rippon et al.,
2006). Thus, stroke may represent either a precipitating
or a triggering event in AD.
While there is an increasing body of knowledge indicat-
ing a strong association between cerebrovascular disease
and AD (Honig et al., 2003; Rippon et al., 2006), the poten-
tial role of apoptosis and cerebral ischemia in AD patho-
genesis has remained unclear. Apoptosis has been firmly
established to enhance Ab production in neuronal and
nonneuronal cells (Barnes et al., 1998; Galli et al., 1998;
Gervais et al., 1999; Guo et al., 2001; LeBlanc, 1995; Sodhi
et al., 2004; Tesco et al., 2003). Thus, apoptotic events in
the brain, such as those induced by stroke and ischemia,
could increase the risk for or trigger AD by driving cerebral
Ab accumulation. Several studies have shown cerebral
ischemia to upregulate APP messages containing the
Kunitz-type protease inhibitor domain between 1 and 21
days after reperfusion (Abe et al., 1991; Kim et al., 1998;
Koistinaho et al., 1996; Shi et al., 2000). Additionally, APP
protein levels were increased between 1 and 10 weeks
after reperfusion (Banati et al., 1995; Kalaria et al., 1993;
Stephenson et al., 1992; Wakita et al., 1992). BACE pro-
tein levels and b-secretase activity have also been shown
to be increased in animal models of acute brain injury,
including cerebral ischemia (Wen et al., 2004) and head
injury, the latter of which is also a risk factor for AD (Blasko
et al., 2004; Chen et al., 2004). More recently, caspase in-
hibition therapy has been shown to prevent brain trauma-
induced increases in Ab peptide (Abrahamson et al., 2006).
Collectively, these findings, taken together with our cur-
rent data, suggest that accumulative insults to the brain
over one’s lifetime would progressively increase risk for
AD by elevating cerebral Ab accumulation via BACE stabi-
lization owing to caspase-mediated depletion of GGA3.
Furthermore, the effect of BACE stabilization on Ab levels
could also be amplified by other events (for example, up-
regulation of APP levels at much later time points, such
as several days after the ischemic event).
We have also shown that GGA3 levels are reduced in
both the temporal cortex and cerebellum of AD patients
(versus controls). The decrease in GGA3 levels was more
pronounced in the temporal cortex as opposed to the
cerebellum, which is relatively spared of AD pathology.Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc. 733
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related with increased levels of BACE only in the temporal
cortex, which is strongly impacted by AD pathology. In
contrast, BACE levels were not significantly increased in
the cerebellum of AD patients as compared to control sub-
jects. These findings suggest that some subjects have
lower levels of GGA3 independently of AD pathology, as
revealed by the analysis of cerebellum. Subjects with lower
levels of GGA3 may be at risk for developing AD, given that
conditions associated with caspase activation (such as
stroke, which is a risk factor for AD) may further decrease
GGA3 levels, thus triggering or precipitating AD pathology.
The contribution of apoptosis to the etiology and path-
ogenesis of AD remains unclear largely due to the difficul-
ties involved in identifying classic apoptotic markers in vivo
(for review see Cribbs et al., 2004; LeBlanc, 2005). This is
most likely due to the long duration of AD and the very
rapid clearance of apoptotic cells. Contradictory results
could be at least partially due to the use of postmortem tis-
sues. Many factors (length of agonal state, collection of
tissue at the end point of the disease, and time interval be-
fore freezing the tissue) may significantly affect the analy-
sis of enzymatic activities. It is also possible that many
senile plaques, which can take many years to form, are
no longer surrounded by apoptotic neurons by the time
of autopsy. On the other hand, genetic evidence for spo-
radic AD, such as the disease associations with DAPK1
(Li et al., 2006), GAPD (Li et al., 2004b), and LOC439999
(Grupe et al., 2006) variants, also point to apoptosis as
a disease-relevant process. While there is increasing evi-
dence for caspase activation in AD brain (for review see
(Cribbs et al., 2004; LeBlanc, 2005), we cannot rule out
the possibility that genetic factors, other posttranslational
mechanisms (such as other proteases), or some combina-
tion of both may contribute to GGA3 depletion in AD brain.
In summary, our studies suggest that elevated BACE
protein levels found in AD patients and animal models of
acute brain injury, including ischemia and acute head
trauma, may be at least partly due to impaired degradation
and stabilization of BACE. This would then lead to in-
creased production of the Abpeptide, thereby contributing
to AD pathogenesis. Since Ab has also been reported to
induce apoptosis, this could result in a vicious cycle that
autopotentiates Ab generation and cell death. Finally, our
in vivo and in vitro data implicate GGA3 as the key player
in regulating degradation of BACE due to its capacity as
a trafficking molecule that delivers BACE to the endoso-
mal-lysosomal system.
EXPERIMENTAL PROCEDURES
Reagent and General Methods
The monoclonal antibody WO2, raised against 1–17 amino acids of the
Ab region, was a gift of Dr. Beyreuther. The anti-Cu,Zn-SOD antibody
was a gift from Dr. Naoyuki Taniguchi. BACE was detected in human
brains by SECB1, which recognizes amino acids 296–310 of BACE
amino terminus (Li et al., 2004a; Yang et al., 2003). Details of standard
methods such as cell cultures, site-directed mutagenesis, transfection,
western blotting, northern blotting, metabolic labeling and pulse-chase734 Neuron 54, 721–737, June 7, 2007 ª2007 Elsevier Inc.experiments, real-time PCR, RNA extraction, and information on other
antibodies and reagents can be found in the Supplemental Experimen-
tal Procedures.
Ab ELISA
Secreted Ab40 was measured in the conditioned media using an Ab40-
specific sandwich ELISA (BioSource International, Camarillo, CA). Ab
concentration was normalized against the concentration of protein in
the cell lysates.
Cycloheximide Degradation Time Course
H4-APP751 cells were treated with CHX (40 mg/ml) only or STS (1 mM) +
CHX during a 30 hr time course. Lysates from each time point were
immunoblotted with the specific antibodies, anti-BACE, anti-TACE,
and the anti-APP antibody A8717.
In Vitro Translation and Recombinant
Caspase-3 Cleavage Assay
The HA-GGA3 pcDNA4 plasmid was a generous gift from Dr. Waguri.
GGA3 was in vitro translated in the presence of [35S]-labeled methio-
nine using TNT Quick Coupled Transcription/Translation Systems as
indicated by the manufacturer (Promega, Madison WI). A reaction con-
taining 5 ml of in vitro translated GGA3 was incubated with or without
200 ng of recombinant caspase-3 (Pharmingen, San Diego, CA) in cas-
pase reaction buffer (20% sucrose, 100 mM NaCl, 20 mM HEPES
(pH 7.4), 0.1% CHAPS, 10 mM DTT, and 1 mM EDTA) at 37C for 2 hr.
The reactions were separated by SDS-PAGE (4%–12% Bis-tricine
gel with MES running buffer; Invitrogen, Carlsbad, CA). The gel was
fixed, dried, and exposed to a phosphorimager screen. The images
were acquired with an FX phosphorimager (Bio-Rad, Hercules CA).
GGA3 in vitro translation was also performed in the presence of cold
methionine. Then, a reaction containing 5 ml of in vitro translated
GGA3 (labeled with cold methionine) was incubated with or without
200 ng of recombinant caspase-3 overnight at 37C. The reactions
were separated by SDS-PAGE. In order to better separate the bands
generated by caspase-3 cleavage, we used 12% Bis-tricine gel and
MOPS running buffer (Invitrogen). Then, the proteins were transferred
to PVDF membrane and WB analysis with anti-GGA3 antibody was
performed.
GGA3 RNAi Silencing
H4 cells stably expressing WT APP-751 or APP containing APPSWE
were transfected with 200 nM siGGA3 (ID #36847; Ambion, Austin
TX), or a 19 bp scrambled sequence was used as siNeg (Silencer
Negative control #1 siRNA, Ambion) using oligofectamine following
the manufacturer’s instructions (Invitrogen). Seventy-two hours later,
GGA3 levels were determined by WB analysis with anti-GGA3 anti-
body (Transduction Laboratories). At the same time point, a sister plate
of the same cells was cotransfected with Myc-tagged BACE plasmid
and siGGA3 or siNeg. After 48 hr the media was replaced. Cells and
media were collected after 72 hr following the cotransfection.
Middle Cerebral Artery Occlusion
Ischemic stroke was induced by MCAO as described before (Wen
et al., 2004). More details can be found in the Supplemental Experi-
mental Procedures.
Human Brain Samples, Protein, and RNA Extraction
Temporal cortexes (20 AD and 19 ND) were obtained from the Brain Do-
nation Program (Sun Health Research Institute, Sun City, AZ). Human
tissue was collected with informed consent of subjects or next of kin
and with ethical approval from the Sun Health IRB. Brain Total RNA
was obtained by RNA minicolumn kit (Qiagen) by following the manu-
factory’s instructions. For protein extraction, a small piece of temporal
cortex was homogenized by 1X RIPA buffer plus PMSF and proteinase
inhibitors mix (Sigma), and protein concentrations were measured by
a protein assay kit (Bio-Rad).
Neuron
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Densitometry analysis was performed on a Macintosh computer using
the public domain NIH Image program (developed at the U.S. National
Institutes of Health and available on the Internet at http://rsb.info.nih.
gov/nih-image/) or using a Versadoc Imager and QuantityOne software
(Bio-Rad). Statistical analysis was performed using Instat3 software.
An unpaired t test was employed for data sets that passed a normality
test. An unpaired t test with Welch correction was employed for data
sets that passed a normality test but had different standard deviations.
A Mann-Whitney test was employed for data sets that did not pass
normality test.
Supplemental Data
The Supplemental Data for this article include Supplemental Experi-
mental Procedures, Supplemental References, and four Figures, and
can be found online at http://www.neuron.org/cgi/content/full/54/5/
721/DC1/.
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